A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Kramski, Marit ^a   Mätz Rensing, Kerstin ^b   Stahl Hennig, Christiane ^b   Kaup, Franz Josef ^b   Nitsche, Andreas ^a   Pauli, Georg ^a   Ellerbrok, Heinz ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; SMALLPOX VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALPOX VIRUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MACACA; MARMOSET; MONKEYPOX VIRUS; NONHUMAN; ORTHOPOXVIRUS; SEROCONVERSION; SMALLPOX VIRUS; SURVIVAL RATE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; ANIMAL; CALLITHRIX; COWPOX VIRUS; DISEASE MODEL; PATHOGENICITY; POXVIRUS INFECTION;

ANIMALS; CALLITHRIX; COWPOX VIRUS; DISEASE MODELS, ANIMAL; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; SMALLPOX VACCINE; SURVIVAL RATE;

EID: 77956401121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010412     Document Type: Article

References (53)

1. WHO (1980) The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. Geneva: World Health Organization.
2. Chantrey J, Meyer H, Baxby D, Begon M, Bown KJ, et al. (1999) Cowpox: reservoir hosts and geographic range. Epidemiol Infect 122: 455-460.
3. Di Giulio DB, Eckburg PB (2004) Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4: 15-25.
4. Parker S, Nuara A, Buller RM, Schultz DA (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2: 17-34.
5. Becker C, Kurth A, Hessler F, Kramp H, Gokel M, et al. (2009) Cowpox virus infection in pet rat owners: not always immediately recognized. Dtsch Arztebl Int 106: 329-334.
6. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, et al. (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350: 342-350.
7. Breman JG (2000) Monkeypox: an emerging infection for humans? In: Scheld WM, Craig WA, Hughes JM, eds. Emerging infections. Washington DC: ASM Press. pp 45-67.
8. Guarner J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, et al. (2004) Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis 10: 426-431.
9. Hazel SM, Bennett M, Chantrey J, Bown K, Cavanagh R, et al. (2000) A longitudinal study of an endemic disease in its wildlife reservoir: cowpox and wild rodents. Epidemiol Infect 124: 551-562.
10. Lewis-Jones S (2004) Zoonotic poxvirus infections in humans. Curr Opin Infect Dis 17: 81-89.
11. Marennikova SS, Shelukhina EM (1976) White rats as source of pox infection in carnivora of the family Felidae. Acta Virol 20: 442.
12. Wolfs TF, Wagenaar JA, Niesters HG, Osterhaus AD (2002) Rat-to-human transmission of Cowpox infection. Emerg Infect Dis 8: 1495-1496.
13. Baxby D (1994) Cowpox: increased incidence or interest? Lancet 343: 543.
14. Baxby D, Bennett M, Getty B (1994) Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol 131: 598-607.
15. Pilaski J, Rosen A, Darai G (1986) Comparative analysis of the genomes of orthopoxviruses isolated from elephant, rhinoceros, and okapi by restriction enzymes. Brief report. Arch Virol 88: 135-142.
16. Kurth A, Wibbelt G, Gerber HP, Petschaelis A, Pauli G, et al. (2008) Rat-to-elephant-to-human transmission of cowpox virus. Emerg Infect Dis 14: 670-671.
17. Kurth A, Straube M, Kuczka A, Dunsche AJ, Meyer H, et al. (2009) Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS One 4: e6883.
18. Czerny CP, Eis-Hubinger AM, Mayr A, Schneweis KE, Pfeiff B (1991) Animal poxviruses transmitted from cat to man: current event with lethal end. Zentralbl Veterinarmed B 38: 421-431.
19. Klingebiel T, Vallbracht A, Doller G, Stierhof YD, Gerth HJ, et al. (1988) A severe human cowpox infection in south Germany. Pediatr Infect Dis J 7: 883-885.
20. Ault A (2003) US smallpox vaccine programme stalls as volunteers balk. Lancet 361: 1626.
21. Qutaishat SS, Olson JL (2003) Bioterrorism preparedness: the smallpox vaccine debate. Clin Med Res 1: 85-86.
22. Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G (2006) Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol 87: 2917-2921.
23. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, et al. (2006) Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748.
24. Quenelle DC, Collins DJ, Kern ER (2003) Efficacy of multiple-or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother 47: 3275-3280.
25. Kern ER (2003) In vitro activity of potential anti-poxvirus agents. Antiviral Res 57: 35-40.
26. Smee DF, Sidwell RW (2003) A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 57: 41-52.
27. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 79: 13139-13149.
28. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46: 1555-1561.
29. Jordan R, Hruby D (2006) Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther 4: 277-289.
30. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, et al. (2004) Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A 101: 15196-15200.
31. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, et al. (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11: 740-747.
32. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, et al. (2004) Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78: 4433-4443.
33. Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, et al. (2006) LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 80: 5179-5188.
34. Matz-Rensing K, Ellerbrok H, Ehlers B, Pauli G, Floto A, et al. (2006) Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol 43: 212-218.
35. Spouge JL (1992) Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci U S A 89: 7581-7585.
36. Rubins KH, Hensley LE, Jahrling PB, Whitney AR, Geisbert TW, et al. (2004) The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A 101: 15190-15195.
37. Downie AW, Saint Vincent L, Goldstein L, Rao AR, Kempe CH (1969) Antibody response in non-haemorrhagic smallpox patients. J Hyg (Lond) 67: 609-618.
38. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Pathogenesis, pathology and immunology of smallpox. Smallpox and its Eradication. Geneva, Switzerland: World Health Organization. pp 121-168.
39. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Human monkeypox and other poxvirus infections of man. Smallpox and its Eradication. Geneva, Switzerland: World Health Organization. pp 1287-1320.
40. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M (1987) Human monkeypox: clinical features of 282 patients. J Infect Dis 156: 293-298.
41. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) The clinical features of smallpox. Smallpox and its Eradication. Geneva, Switzerland: World Health Organization. pp 1-68.
42. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, et al. (2005) Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79: 7845-7851.
43. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L (2001) The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81: 1581-1600.
44. Rylands AB (1997) Handbook: Marmosets and Tamarins in Biomedical Research. The Callitrichidae: A Biological Overview. Salisbury, UK.: DSSD Imagery. pp 1-2.
45. Stahlmann R, Neubert R (1995) Value of non-human primate data. Hum Exp Toxicol 14: 146-147.
46. Carrion R, Jr., Brasky K, Mansfield K, Johnson C, Gonzales M, et al. (2007) Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol 81: 6482-6490.
47. Carey GJ, Costall B, Domeney AM, Jones DN, Naylor RJ (1991) Behavioral Effects of Anxiogenic Agents in the Common Marmoset. Pharmacol Biochem Behav 42: 143-153.
48. Lever MS, Stagg AJ, Nelson M, Pearce P, Stevens DJ, et al. (2008) Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol 89: 171-179.
49. Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent SJ, et al. (2008) Virus-specific T-cell immunity correlates with control of GB virus B infection in marmosets. J Virol 82: 3054-3060.
50. Genain CP, Hauser SL (1997) Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J Mol Med 75: 187-197.
51. van Vliet SA, Vanwersch RA, Jongsma MJ, Olivier B, Philippens IH (2008) Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol 18: 383-389.
52. Kettle S, Blake NW, Law KM, Smith GL (1995) Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206: 136-147.
53. Smee DF, Bailey KW, Wong M, Sidwell RW (2000) Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res 47: 171-177.